Somatostatin Receptor Positive clinical trials

Explore recruiting somatostatin receptor positive clinical trials.

Recruiting somatostatin receptor positive studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Somatostatin Receptor Positive trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase I trial with 177Lu-DOTA-TATE and olaparib in somatostatin receptor positive tumours

Sweden

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Multicentre Surveillance Study to Evaluate the Long-term Safety in Participants who Have Been Previously Treated with 177Lu-IPN01072 in an Ipsen-sponsored Clinical Study

France

Therapeutic use (Phase IV) EU CTIS Study details

A multicenter open-label study to evaluate safety and dosimetry of Lutathera in adolescent patients with somatostatin receptor positive gastroenteropancreatic neuroendocrine (GEP-NET) tumors, pheochromocytoma and paragangliomas

France, Spain, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Multicenter, Open-label, Interventional Phase I Trial to Determine the Dose and Evaluate the Pharmacokinetics (PK) and Safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as Monotherapy or Following Standard of Care (SoC) for the Treatment of Somatostatin Receptor-positive Tumors in the Pediatric Population (KinLET)

Italy, Spain, France

Human Pharmacology (Phase I)- Other EU CTIS Study details

Efficacy, safety and patient-reported outcomes of peptide receptor radionuclide therapy with 177Lu-edotreotide compared to everolimus in somatostatin receptor positive neuroendocrine tumors of the lung and thymus. The LEVEL trial

Spain, France, Italy, Belgium

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of Lutathera in patients with Grade 2 and Grade 3 advanced GEP-NET (NETTER-2)

Italy, Spain, Netherlands, Germany, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Somatostatin Receptor Positive trials by city

Somatostatin Receptor Positive in Toronto Somatostatin Receptor Positive in Vancouver Somatostatin Receptor Positive in Montreal Somatostatin Receptor Positive in Calgary Somatostatin Receptor Positive in Edmonton Somatostatin Receptor Positive in Ottawa Somatostatin Receptor Positive in Winnipeg Somatostatin Receptor Positive in Quebec City Somatostatin Receptor Positive in Hamilton Somatostatin Receptor Positive in Kitchener Somatostatin Receptor Positive in London Somatostatin Receptor Positive in Halifax Somatostatin Receptor Positive in New York Somatostatin Receptor Positive in Los Angeles Somatostatin Receptor Positive in Chicago Somatostatin Receptor Positive in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease